Individuals complete an online consultation and, if approved, receive a prescription for semaglutide
Semaglutide is one of the most widely studied GLP-1 medications and remains a foundational option for medical weight management
Novo Nordisk submitted CagriSema for FDA approval, with a decision expected in late 2026
For MRI, two values were not registered from MK-801 group, two values were not registered from GLP-1 group and two values were not registered from GLP-1MK-801 group due to MRI instrumental error
These findings are consistent with what we are seeing broadly that medications like tirzepatide are not just weight loss drugs but have meaningful cardiometabolic benefits, said Kevin Shah, MD, a cardiologist and the program director of Heart Failure Outreach at MemorialCare Heart & Vascular Institute at the Long Beach Medical Center, in a previous interview with Healthline